Allarity Therapeutics Files 8-K Report
Ticker: ALLR · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1860657
Sentiment: neutral
Topics: regulatory-disclosure, financial-exhibits
TL;DR
Allarity Therapeutics filed an 8-K, mostly for financial docs. Nothing major revealed yet.
AI Summary
On June 25, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a regulatory disclosure. No specific financial figures or significant events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing serves as a public record of regulatory disclosures and financial exhibits for Allarity Therapeutics, Inc., providing transparency to investors.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain information about significant financial changes, risks, or strategic shifts.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- June 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41160 (identifier) — Commission File Number
- 24 School Street, 2nd Floor, Boston, MA 02108 (address) — Address of principal executive offices
- (401) 426-4664 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for regulatory disclosure, specifically concerning financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 25, 2024.
What is the state of incorporation for Allarity Therapeutics, Inc.?
Allarity Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Allarity Therapeutics, Inc.?
The Commission File Number for Allarity Therapeutics, Inc. is 001-41160.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive office address is 24 School Street, 2nd Floor, Boston, MA 02108.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-06-26 08:00:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea020849301-8k_allarity.htm (8-K) — 24KB
- ea020849301ex99-1_allarity.htm (EX-99.1) — 20KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-055919.txt ( ) — 230KB
- allr-20240625.xsd (EX-101.SCH) — 3KB
- allr-20240625_lab.xml (EX-101.LAB) — 34KB
- allr-20240625_pre.xml (EX-101.PRE) — 22KB
- ea020849301-8k_allarity_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 25, 2024, Allarity Therapeutics, Inc. (the "Company"), issued a press release announcing that multiple patients in the Company's Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have been on treatment for more than 30 weeks. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated June 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: June 26, 2024 2